Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02119663
Title A Study of Ruxolitinib in Pancreatic Cancer Patients
Recruitment Terminated
Gender both
Phase Phase III
Variant Requirements No
Sponsors Incyte Corporation
Indications

pancreatic adenocarcinoma

Therapies

Capecitabine

Capecitabine + Ruxolitinib

Age Groups: adult
Covered Countries USA | FRA | AUT


No variant requirements are available.